Study Title and Description
Exemestane for breast-cancer prevention in postmenopausal women.
Key Questions Addressed
|2||Key Question 2. In adult women without preexisting breast cancer, what is the effectiveness and comparative effectiveness of medications to reduce risk for primary breast cancer on improvement in short- and long-term health outcomes, including invasive breast cancer, noninvasive breast cancer (including ductal carcinoma in situ), breast cancer mortality, all-cause mortality, and other beneficial outcomes (such as reduced fractures caused by certain medications and improved quality of life)? Key Question 2a. Does the effectiveness of risk-reducing medications vary by timing of initiation or duration of use? Key Question 2b. Does the effectiveness of risk-reducing medications persist beyond discontinuation of use?|
|3||Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?|
|4||Key Question 4. How do outcomes vary by population subgroups?|
Primary Publication Information
|Title||Exemestane for breast-cancer prevention in postmenopausal women.|
|Author||Goss PE., Ingle JN., Alés-Martínez JE., Cheung AM., Chlebowski RT., Wactawski-Wende J., McTiernan A., Robbins J., Johnson KC., Martin LW., Winquist E., Sarto GE., Garber JE., Fabian CJ., Pujol P., Maunsell E., Farmer P., Gelmon KA., Tu D., Richardson H.|
|Country||Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA. email@example.com|
Pubmed ID: 21639806
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-4
Results & Comparisons
No Results found.